Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischaemic heart disease

• 資料種別: 博士論文
• タイトル: Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischaemic heart disease
• 著者・編者: Nishikawa, Tatsuya; Fujino, Masashi; Nakajima, Ikutaro; Asaumi, Yasuhide; Kataoka, Yu; Anzai, Toshihisa; Kusano, Kengo; Noguchi, Teruo; Goto, Yoichi; Nishimura, Kunihiro; Miyamoto, Yoshihiro; Kiso, Keisuke; Yasuda, Satoshi
• 著者標目: Nishikawa, Tatsuya; Fujino, Masashi; Nakajima, Ikutaro; Asaumi, Yasuhide; Kataoka, Yu; Anzai, Toshihisa; Kusano, Kengo; Noguchi, Teruo; Goto, Yoichi; Nishimura, Kunihiro; Miyamoto, Yoshihiro; Kiso, Keisuke; Yasuda, Satoshi
• 出版事項: European Society of Cardiology|Oxford University Press
• 出版年月日等: 2016-10-14
• 出版年（W3CDTF）: 2016-10-14
• 並列タイトル等: 虚血性心疾患患者で植込み型除細動器移植後の長期予後に及ぼす冠動脈慢性完全閉塞病変の影響; Prognostic impact of chronic total coronary occlusion on long-term outcomes in implantable cardioverter-defibrillator recipients with ischemic heart disease
• タイトル（掲載誌）: EP Europace
• 巻号年月日等（掲載誌）: 19 7
• 掲載巻: 19
• 掲載号: 7
• 掲載ページ: 1153-1162
• ISSN（掲載誌）: ISSN : 1532-2092; ISSN : 1099-5129
• 授与機関名: 徳島大学
• 授与年月日: 2016-11-24
• 報告番号: 甲第3001号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: CTO; 植込み型除細動器; 虚血性心疾患; 血行再建; 心筋viability; Chronic total occlusion; implantable cardioverter-defibrillator; ischemic heart disease; revascularization; myocardial viability
• 対象利用者: 一般
• 一般注記: Aims The prognostic impact of chronic total coronary occlusion (CTO) on implantable cardioverterdefibrillator (ICD) recipients remains unclear. Methods and Results Eighty-four consecutive patients with ischemic heart disease who received ICD therapy for primary or secondary prevention were analyzed. We investigated all-cause mortality and major adverse cardiac events (MACEs) including cardiac death, appropriate device therapy, hospitalization for heart failure, and ventricular assist device implantation. Of the study patients (mean age 70 ± 8 years; 86% men), 34 (40%) had CTO. There were no significant differences in age, left ventricular ejection fraction (LVEF), NYHA functional class III or IV status, and proportion who underwent secondary prevention between patients with CTO (CTO group) and without CTO (non-CTO group). During a median follow-up of 3.8 years (interquartile range 2.7 to 5.4 years), the CTO group tended to have a higher MACE rate (log-rank P=0.054) than the non-CTO group. Within the CTO group, there was no difference in the MACE rate between patients with and without viable myocardium. In patients with ICD for secondary prevention (n=47), 16 patients (34%) with CTO had a higher MACE rate than patients without CTO (logrank P<0.01). Cox proportional hazards regression analysis showed that the presence of CTO, but 3 not LVEF, was associated with a higher MACE rate. Multivariate analysis showed that the presence of CTO was a predictor of MACE (P<0.05). Conclusion In patients with ischemic heart disease receiving ICD implantation, the presence of CTO has an adverse impact on long-term prognosis, especially as secondary prevention.
• 記録形式（IMT）: application/pdf
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（DOI）: 10.1093/europace/euw213
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 徳島大学 : 徳島大学機関リポジトリ

目次

http://repo.lib.tokushima-u.ac.jp/files/public/11/110000/20170929142305468611/LID201701261001.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/110000/20180615110733353701/k3001_fulltext.pdf fulltext